April 2019 Issue Table Of Contents

From The Editor

• Big Wins Are Not Enough To Repair Biopharma’s Broken Image

Feature Articles

• Deborah Waterhouse’s Long Journey To CEO Of ViiV Healthcare
• Garo Armen And Audacity At Agenus
• What Can Be Done To Save Biopharma’s Reputation?

Capitol Perspectives

• Countering Provider Consolidation

CEO Corner

• Balancing Hyperbole With Reality: A CEO’s Perspective

From Principles and Policy to Execution

• Measurable Population Wellness Will Require Comprehensive Care, Not Piecemeal Healthcare

Companies To Watch

• Vyome Therapeutics

Industry Research

• Are Outsourcers Interested In Changing Their CRO Mix?

Inside The Industry

• The Rollercoaster Ride Of A Biotech CEO
• Connecting Women Who Are Boardroom Ready
• Common Chronic Diseases: What Can Orphan Drugs Teach Us?
• Laying the Foundation For One-Time Therapeutic Reimbursement
• Biopharma IPR Trends – 2019 Mid-Year Update
• Are Preferred Provider Agreements the Best Model for Outsourced Manufacturing?
• 5 Points For Devising An Effective Pharma 4.0 Program Proposal

Leadership Lessons

• How GREAT Is Your Resistance To Getting A Yes?

Ask The Board

• Over The Next Few Years, Should Biopharmas Broaden Their Definition For What They Define As “Core?”
• There Are Some Trends We Know To Expect, But What’s A Trend You Fear May Be Being Overlooked?
• What Are Some Of The Key Components In Gaining FDA Fast Track Designation For A Therapeutic?